The only known mechanism by which cisplatin lesions are removed from DNA in mammalian cells is by NER. This involves steps of damage recognition, opening of DNA, and incision on both sides of a lesion. The core reaction requires the proteins XPA, RPA, XPC-hHR23B, TFIIH, ERCC1-XPF and XPG [4, 5] . To analyse the NER capacity of cisplatin-hypersensitive human testis tumour cell lines, we measured the ability of cell extracts to form dual incisions flanking an adduct. A plasmid was used containing a single 1,3-intrastrand d(GpTpG) cisplatin cross-link (Pt-GTG), which is repaired efficiently by the mammalian NER system [6] . The 24-32 nucleotide products produced by dual incision are detected by end-labelling with the aid of a complementary oligonucleotide [7] , separated on a denaturing polyacrylamide gel and quantified. 10, 11) . All findings were reproduced in additional experiments using at least four independent extracts from each tumour cell line. The results show that the testis tumour cell lines have unusually low constitutive levels of NER. This is consistent with observations that these cells have a low capacity to remove cisplatin adducts [2, 3] .
Reduced amounts of XPA protein and ERCC1-XPF complex in the testis tumour cells
Our hypothesis was that the low NER capacity of the testis tumour cells might be caused by a reduced level of one or more core repair factors. Levels of NER proteins were measured by immunoblotting a panel of cells including the two testis tumour cell lines 833K and GCT27, the bladder tumour line MGH-U1, HeLa cells and a normal lymphoblastoid cell line 705ori. In testis tumour cell lines, most of the repair proteins were present at levels equivalent to or even greater than the other cell lines, as shown for the RPA p34 subunit (Figure 2a ), XPG and subunits of TFIIH ( Figure 2b ) and XPC protein (Figure 2c ). The RPA and TFIIH subunits can be regarded as internal controls for the amount of nuclear protein added, as they are housekeeping proteins necessary for DNA replication and transcription, respectively. Two factors were consistently found in reduced amounts in testis tumour cells. The amount of XPA protein was reduced to 25% or less in 833K and GCT27 compared with MGH-U1, HeLa and 705ori cells (Figure 2d ). In addition, the amounts of ERCC1-XPF factor were reduced in 833K and GCT27 cells compared with the other three cell lines (Figure 2e ).
Restoration of testis tumour cell extract NER with purified XPA protein
To determine whether the NER deficiency of the testis tumour cell extracts could be restored, extracts were supplemented with the proteins that were present in low amounts, XPA and ERCC1-XPF. Addition of 10 ng XPA markedly stimulated the dual incision activity of the testis tumour cell extracts (Figure 3a, lanes 7,8 and lanes 13,14) , with little effect on the bladder tumour MGH-U1 cell extract (lanes 1,2) . Quantification showed an approximately fourfold stimulation by 10 ng XPA in the testis tumour cell extracts. As a control, XPA protein conferred repair capacity on completely NER-defective XP group A extract (lanes 19, 20) . Addition of ERCC1-XPF complex also stimulated repair by extracts from the cell lines, but the effect was less marked. Supplementation with purified ERCC1-XPF resulted in twofold stimulation of 833K extract repair activity (Figure 3b, lanes 5-8) , as well as a nearly twofold stimulation of MGH-U1 extract repair ( Figure 3b, lanes 1-4) . As a control, ERCC1-XPF fully restored repair to ERCC1-defective control cell extracts (Figure 3b , lanes 9-12). ERCC1-XPF had a modest effect on GCT27 cell extract (Figure 3c , compare lanes 3,5). Quantitative immunoblotting, using purified proteins as standards, showed that 40 µg MGH-U1 protein extract contained about 10 ng of XPA and about 20 ng of ERCC1-XPF and so the amounts of proteins added in Figure 3 are in the physiological range.
Experiments with combinations of factors showed that XPA had by far the most pronounced effect on repair by the testis tumour cell extracts. For example, addition of 40 ng XPA protein increased the dual incision activity of GCT27 extract by 6-fold, with a 1.8-fold further enhancement given by combination with ERCC1-XPF complex ( Figure 3c , compare lanes 3,4,6). The reaction was specific and repair was not enhanced significantly by other NER proteins. Addition of XPG protein did not influence the dual incision activity of GCT27 or 833K extracts ( Figure 3c , compare lanes 3,7 and 9,13). Similarly, addition of XPC or XPC-hHR23B complex did not stimulate repair by 833K and GCT27 extracts (data not shown).
Implications for tumour sensitivity and chemotherapy
These results show that the low amount of XPA protein in the testis tumour cell lines is a sufficient explanation for their low NER capacity and indicate that this is a major factor determining their drug sensitivity. Consistent with this, XPA-defective cells are hypersensitive to killing by cisplatin-DNA lesions [8, 9] . The XPA protein is at the (a) Autoradiograph showing repair of a cisplatin adduct after incubation with extract protein (20 or 40 µg at 2 or 4 mg/ml) from HeLa cells, the bladder cancer cell line MGH-U1, the testis tumour lines 833K and GCT27 and the NER-defective XP group G AG08802 cell line. Reaction mixtures contained either 50 ng of a duplex plasmid with the Pt-GTG adduct (+) or 50 ng control DNA synthesised without the adduct (-). Dual incision products were detected by direct labelling as described [7] and are indicated by the bracket on the left. Arrows point to the bands arising from cleavage at the three most frequent 5′ incision sites in HeLa cells to yield fragments 26, 29 and 30 nt long. core of the NER machinery and interacts with damaged DNA as well as with the other NER factors RPA, TFIIH and ERCC1 [4, 5] . Human cells with inactivating mutations in the XPA gene [10] or knockout mice with disruptions in XPA [11, 12] have absolutely no capacity for NER and are defective in removing cisplatin lesions from their genomes [9, 13] . Coupled with other data indicating that the amount of XPA protein expressed in fibroblasts is a limiting factor for NER capacity [14] [15] [16] , it is reasonable to expect that the amount of XPA in testis tumour cells significantly influences cisplatin sensitivity.
Cell lines derived from human testicular germ cell tumours retain their sensitivity to many different chemotherapeutic drugs and to radiation, reflecting the clinical response [17] . Many potential sensitising mechanisms have been investigated. For cisplatin these include not only DNA repair but intrinsic permeability to the drug, levels of intracellular scavengers, and pathways which promote apoptosis. For example, testis tumour cells (including those used in this study) contain high levels of non-mutated p53 and it has been suggested that the sensitivity to a broad range of drugs and radiation is largely due to a propensity to undergo apoptosis after DNA damage [18, 19] . Other studies have concluded that there is no correlation between cisplatin sensitivity and p53 status of testis tumour cells [20, 21] . Although the XPA protein is present in reduced amounts in the testis tumour cell lines, the level at which this is controlled is not known. Tissue-specific variations in XPA mRNA levels may exist and it has been reported that expression of XPA mRNA in normal mammalian testis tissue is relatively low [22] , raising the possibility that even normal testis tissue has a low level of XPA protein and hypersensitivity to cisplatin. This requires further investigation with additional testis tumour cell lines and normal tissues. Overexpression of the relevant genes in testis tumour cell lines will give a fuller understanding of the involvement of NER factors in cellular hypersensitivity.
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These observations further suggest that specific inhibition of XPA could sensitise other types of tumours to cisplatin and thereby broaden the usefulness of its class of chemotherapeutic agents. XPA is a unique potential target for chemotherapy amongst the core NER factors because it has no known involvement in other cellular pathways. XPA knockout mice, for example, are only distinguishable from normal mice by their sensitivity to UV light and chemical carcinogens [11, 12] . This apparently unique role of XPA is in sharp contrast to the components RPA, TFIIH, XPG and ERCC1-XPF, each of which has some other function in a separate process of DNA replication, transcription, recombination, or another repair pathway [5, 23] . Cellular reduction of XPA protein levels should therefore specifically reduce NER without affecting other aspects of DNA metabolism. Targeted inhibition of the activity of XPA in repair might be achieved, for example, by using a short peptide or small molecule inhibitor to disrupt either the critical XPA-RPA interaction or the binding of XPA to damaged DNA.
Supplementary material
Quantification of the data from Figure 3 and additional methodological details are published with this paper on the internet. 
Supplementary materials and methods

Cells and cell extracts
The human testis germ cell tumour lines GCT27 (testis primary, embryonal carcinoma) and 833K (testis abdominal metastasis, embryonal carcinoma, teratoma) and the bladder cancer cell line MGH-U1 (transitional-cell carcinoma) were described previously [S1]. Both testis tumour cell lines have high levels of functional p53 [S2] as well as levels of the mismatch repair proteins MSH2, MLH1 and PMS2 that are in the normal range (P. Maisuria and B.K., unpublished data). These cell lines and the ERCC1-defective cell line 43-3B [S3] were grown as monolayers in 175 cm 2 tissue culture flasks in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum. The lymphoblastoid cell line 705ori was from a repair-proficient donor [S4] . Repair properties of the lymphoblastoid GM2345 cell line from the XPA-defective patient XP2OS, and the lymphoblastoid AG08802 cell line from the XPG-defective patient XP20BE have been described [S5,S6] . These cell lines were grown in suspension in RPMI 1640 medium with 10% fetal calf serum. HeLa cells were grown in suspension in RPMI 1640 medium with 5% fetal calf serum. Whole cell extracts were prepared as described [S7] . Care was taken to insure that cells were in the logarithmic growth phase at the time of harvesting.
Nucleotide excision repair in vitro
Covalently closed circular DNA ( Figure S1a ) containing a single 1,3-intrastrand d(GpTpG) cisplatin crosslink (Pt-GTG) or lacking damage (Con-GTG) was produced as described, using M13mp18GTGx bacteriophage Table S1 Quantification of data.* Quantification of data from Figure 3a XPA protein (ng) MGH-U1 833K GCT27 - Figure 1a point to the position of the bands arising from cleavage at the three major 5′ incision sites, which are the major products in HeLa cells. There are several reasons for a more complex pattern of bands spanning the region from 24-32 nt, as found for other adducts. There is a limited shortening of primary incision products in the extracts, the detection method involves end-filling by dCTP which may not always give full length products and could in theory give rise to three shorter bands for each primary product, and there are probably some minor 5′ incision sites. The results are quantified as the sum of the entire band pattern, which takes into account all of these factors. Figure S1b ). The excision products were radiolabelled with 0.13 units Sequenase v2.0 DNA polymerase and 2 µCi [α-32 P]dCTP, separated on a denaturing 14% polyacrylamide gel and visualized by autoradiography as described [S9] . Results were quantified with a phosphorimager or by densitometry.
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GTCGACCAGGCCTCTTCTTCTGTGCACTCTTCTTCTCCCCAGG CAGCTGGTCCGGAGAAGAAGACACGTGAGAAGAAGAGGGGTCC
SDS-PAGE and immunoblots
Protein extracts were prepared by lysing 5 × 10 6 cells on ice in 40 µl of buffer containing 50 mM Tris-HCl pH 7.5, 250 mM NaCl, 1 mM EDTA, 0.1% Triton X-100 (1% Triton X-100 for XPC), 2 µg/ml aprotinin, 2 µg/ml leupeptin, 1 µg/ml pepstatin and 97 µg/ml PMSF. After 30 min incubation the cells were centrifuged at 14,000 × g for 20 min at 4°C, the supernatant was recovered and protein content determined by the Bradford method. For immunoblotting, protein extracts were separated on SDS 10% polyacrylamide gels and transferred to Immobilon P membranes. Primary rabbit polyclonal or mouse monoclonal antibodies were as follows: XPA, 1/10,000 dilution of polyclonal antibody CJ1, raised against recombinant human XPA protein (C.J. Jones, unpublished). XPC, 1/2,000 dilution of polyclonal antibody RW028 raised against residues 96-299 of human XPC protein (D. Batty, unpublished). XPG, 1/500 dilution of monoclonal antibody 8H7 (E. Evans and J. Steel, unpublished). XPB 1/1,000 dilution of monoclonal antibody 2G12 and p62, 1/10,000 of monoclonal antibody 3C9, both provided by J-M. Egly. RPA p34 subunit, 1/1,000 dilution of monoclonal antibody 34A [S10] . XPF, 1/5,000 dilution of polyclonal antibody RA1 raised against residues 571-905 of human XPF protein (L. Fullerton and R. Ariza, unpublished). ERCC1, 1/1,500 dilution of polyclonal antibody RW017 [S11] . The membranes were incubated with the primary antibody for 1 h, followed by incubation for 1 h with either 1/25,000 dilution of peroxidase-labelled anti-mouse IgG or 1/25,000 dilution of peroxidase-labelled anti-rabbit IgG (both from Sigma). For detection of XPC protein the secondary antibody was diluted to 1/75,000. Bands were revealed with an ECL chemiluminescence kit (Amersham).
